Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

06/22/2026, 6:10 PM • The Motley Fool

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Moderna's stock has surged over 100% this year as the company diversifies beyond COVID-19 vaccines using its mRNA platform. Key catalysts include FDA approval of mFlusiva (flu vaccine) expected August 5, 2026, and the European Commission's approval of mCOMBRIX (flu-COVID combination vaccine). The company's most transformative opportunity lies in cancer vaccines, with phase 3 data for mRNA-4157 expected later in 2026. Despite 260% revenue growth in Q1 2026, Moderna remains unprofitable but has $7.5 billion in cash and targets company-wide breakeven by 2028.

06/20/2026, 7:30 AM • The Motley Fool

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Three stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings with expansion opportunities. AMD is capitalizing on AI growth through its server CPU leadership and gaining market share from Intel.

06/18/2026, 1:30 AM • The Motley Fool

FDA Panel Set To Debate Moderna Flu Shot

The FDA's VRBPAC panel will meet on June 18 to review Moderna's mRNA-based flu vaccine (mFlusiva/mRNA-1010) for adults 50 and older. The vaccine met all efficacy criteria in trials, but the panel will scrutinize the choice of standard-dose flu vaccine as a comparator and efficacy data limitations in older adults. Moderna seeks full approval for ages 50-64 and accelerated approval for 65+, with an FDA decision deadline of August 5.

06/17/2026, 8:23 AM • Benzinga

Stock Market Today, June 16: Nvidia, Broadcom, and Micron Technology Lead Drop in Nasdaq

The Nasdaq fell 1.15% on tech and chip weakness, with major semiconductor stocks like Nvidia, Broadcom, and Micron Technology declining due to profit-taking. The S&P 500 dropped 0.57%, while the Dow Jones rose 0.64% as investors rotated toward industrial, transportation, and financial sectors. CoreWeave surged nearly 10% on bullish analyst sentiment, while Robinhood Markets slid following layoff announcements. The Federal Reserve began its first meeting under new Chair Kevin Warsh.

06/16/2026, 5:24 PM • The Motley Fool

Dow Jones Hit Record Highs As Oil Drops To $77: Stock Market Today

U.S. stocks showed mixed performance on Tuesday as investors rotated out of technology into financials, utilities, and industrials. The Dow Jones reached record highs at 52,185.49, while the Nasdaq 100 declined 1.4%. Oil prices fell to $77/barrel on expectations of a Strait of Hormuz reopening deal. Federal Reserve Chair Kevin Warsh prepares for his first policy meeting with markets pricing in a 97% probability of unchanged rates.

06/16/2026, 1:12 PM • Benzinga

Moderna Strengthens Commercial Strategy As Pipeline Advances

Moderna announced organizational changes with President Stephen Hoge taking expanded oversight of R&D, manufacturing, and commercial operations. The company reported Q1 adjusted loss of $1.18 per share (better than expected) and revenue of $389 million (exceeding estimates). Moderna reiterated 2026 revenue growth guidance of up to 10% and expects potential launches of three new products in 2027-2028, including flu-COVID combination and norovirus vaccines. The company also anticipates key clinical milestones for its oncology and rare disease candidates.

06/16/2026, 12:56 PM • Benzinga

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.

06/12/2026, 2:30 AM • The Motley Fool

Does Moderna Need to Start Making Money?

Moderna is posting billions in annual losses as COVID-19 vaccine sales decline, but the article argues this may be a sound strategy. The company has a robust pipeline of 30+ vaccines and therapeutics in development, aims to reach 10 commercial products within years, is cutting costs aggressively, and maintains $7.5 billion in cash. Management projects the company will achieve cash flow positivity by 2028.

06/09/2026, 7:11 AM • The Motley Fool

Broadcom’s Guidance Miss Exposes the Fragility of the AI Trade

Broadcom's guidance miss on Q3 AI chip sales ($16B vs. $17.2B expected) triggered a sharp market rotation away from expensive AI semiconductors into defensive and value stocks. Despite beating on current quarter earnings, the company's soft forward guidance spooked investors already concerned about stretched valuations (P/E at 42.53, near dot-com peak levels). The sell-off dragged down the entire chip sector while the Dow surged on defensive names, exposing how little margin for error remains in the AI trade amid rising Treasury yields and hawkish Fed expectations.

06/04/2026, 2:01 PM • Investing

Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls

Moderna announced positive five-year follow-up results from its Phase 2b trial showing its melanoma vaccine candidate (intismeran autogene plus KEYTRUDA) reduced recurrence or death risk by 49% compared to KEYTRUDA alone. The company also expanded its partnership with CEPI to develop a Bundibugyo ebolavirus vaccine, with CEPI committing up to $50 million. Despite the positive news, Moderna's stock fell 2.78% to $45.88.

06/01/2026, 12:39 PM • Benzinga

Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million

Plustick Management acquired 499,596 shares of Anterix (ATEX) for approximately $15.81 million in Q1 2026, making it one of the fund's largest holdings. The investment reflects confidence in Anterix's spectrum commercialization business, bolstered by FCC approval to expand 900 MHz broadband allocation from 6 MHz to 10 MHz, a $123 million contracted pipeline, and a prospective $3 billion opportunity pipeline across 60+ potential customers.

05/29/2026, 7:12 PM • The Motley Fool

Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to address the significant unmet medical need in this rare cancer indication.

05/28/2026, 1:00 PM • GlobeNewswire

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.

05/21/2026, 8:00 AM • GlobeNewswire

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool